Actavis Receives Approval Of Generic Wellbutrin XL® 300mg In The U.S.

Actavis Group, the international generic pharmaceuticals company, recently announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual US sales of brand and generic Wellbutrin XL 300mg were US$581M for the 12 months ending June 2008 according to IMS Health data.

Commenting on the new approval, Douglas Boothe, Chief Executive Officer of Actavis, Inc. said: "Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group's focus and expertise in bringing complex controlled-release technologies to the marketplace."

About Actavis
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

SOURCE: Actavis Group